1 completed, 1 unknown. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow ATGC Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines ATGC-110, Xeomin® - Glabellar Frown Lines | Phase 3 | Unknown | ATGC Co., Ltd. | 300 | 2022-10-11 | 2023-02-03 |
| A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines Botulinum toxin type A - Glabellar Frown Lines | Phase 1 / Phase 2 | Completed | ATGC Co., Ltd. | 60 | 2019-11-01 | 2020-07-09 |
Botulinum Toxins, Type A (2) · incobotulinumtoxinA (1)
South Korea (2)